

DST and Lupin join hands over Migraine and Psoriasis

BSE: 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
-------------	------------	------------------	-------------------

Mumbai, April 27, 2007: Lupin Ltd. announced today that the Department of Science and Technology (DST), Government of India and Lupin have joined hands for the clinical development of Lupin's Migraine and Psoriasis projects. After an exhaustive review and evaluation of the proposals received from the industry, the DST has selected two clinical development programs of Lupin for funding, one each in the disease areas of migraine and psoriasis. While the migraine project involves conducting of Phase III clinical trials of Lupin's LL-2011 (*Amigra*, a herbal formulation being developed as a nasal spray) for prophylactic treatment of migraine, the collaboration on psoriasis will support the extended Phase I and Phase II trials of LL-4218, a pure compound derived from a herbal source, for the treatment of chronic stable plaque type of psoriasis. The DST has committed over Rs. 100 million to support Lupin's clinical development projects, which are expected to be completed in two years.

Speaking of the collaboration, Dr. Desh Bandhu Gupta, Chairman, Lupin Limited reiterated the Company's commitment to support the discovery and development of new drugs for human healthcare and greatly appreciated the support extended by the Government of India in the clinical development of Lupin's anti-migraine and anti-psoriasis agents.

About Lupin

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the nine-month period ended December 2006, the Company's Revenues and Profit after Tax were Rs.14,985 million (US\$ 335 million) and Rs.1,650 million (US\$ 37 million) respectively.

For further information contact:

Raju Kane

The Source

Tel. +91 22 24901327/28

Telefax: +91 22 24901325

Mobile: +91 98200 45656

E-mail: rajukane@sourcepr.com